Opinion
Video
Treatment of Generalized Pustular Psoriasis (GPP)
Author(s):
Kanya Oul shares how her generalized pustular psoriasis (GPP) was initially treated and Drs Tina Bhutani and Scott Boswell discuss available treatment options for GPP.
This is a video synopsis/summary of a panel discussion involving Tina Bhutani, MD; J. Scott Boswell, MD; and Kanya Oul, RN.
The discussion delves into various treatments for generalized pustular psoriasis (GPP), with patient Kanya sharing her experiences with different medications. Initially, she relied on acitretin and cyclosporine, which helped stabilize her condition without notable side effects, aside from restrictions like blood donations. Discontinuing acitretin took 5 years to clear from her system, a consideration for future plans like pregnancy. The conversation recalls frequent blood draws during treatment, a common experience for patients, especially challenging for teenagers.
Traditional treatments like acitretin and cyclosporine require careful monitoring due to their immunosuppressive nature, contrasting with newer options like biologics. While not FDA-approved for GPP in the U.S., biologics show promise, particularly in targeting specific cytokines responsible for psoriasis variants. The discussion emphasizes the importance of early diagnosis and treatment to prevent severe complications like sepsis and organ distress.
In managing patients with GPP, a continuous treatment approach is preferred, with a watchful eye for flare-ups. Topical treatments are cautiously used alongside systemic options, balancing efficacy with potential side effects. Quick diagnosis is crucial to avoid mistaking GPP for other conditions, preventing worsening symptoms and complications. Overall, the conversation highlights the evolving landscape of GPP treatment, with a focus on personalized care and early intervention.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
